[Somatostatin analogue in the treatment of neuroendocrine gut tumors].
Somatostatin is a short-acting natural peptide secreted by specialized cells in the GI tract, the central and peripheral nervous systems, and a variety of other tissues. Its many actions include suppression of the secretion of GH, TSH, GI hormones, and inhibition of GI exocrine secretion. A long-acting analogue developed by Sandoz (Sandostatin, SMS 201-995) has been used to treat acromegaly and neuroendocrine tumors. We report our experience with it in carcinoid tumors (4 cases), glucagonomas (2), gastrinoma (1), VIPoma (1) and nonfunctioning islet cell tumor (1). It was given by continuous subcutaneous infusion, using a small portable pump, in doses ranging from 300 to 1500 mcg/day, without significant side-effects. 7 of the 9 patients had complete relief of symptoms, and tumoral hormone secretion decreased in 4 of the 5 in whom it was measurable, but there was no evidence of tumor regression. SMS 201-995 is useful for the symptomatic treatment of patients with neuroendocrine gut tumors.
Ben Yosef
R
R
Dept. of Oncology, Hadassah Medical Center, Jerusalem.
Glaser
B
B
Catane
R
R
D007516:Adenoma, Islet Cell / Q000188:drug therapy; D002276:Carcinoid Tumor / Q000188:drug therapy; D015408:Gastrinoma / Q000188:drug therapy; D005935:Glucagonoma / Q000188:drug therapy; D006801:Humans; D007260:Infusion Pumps; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D003969:Vipoma / Q000188:drug therapy
D015282:Octreotide